Lanosterol 14-alpha demethylase
Protein in Aspergillus that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
- Genes: 3
Who is on it, and how far along
Every drug ChEMBL records acting on CYP51, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Isavuconazonium | Approved | Astellas Pharma | Small molecule | InhibitorLanosterol 14-alpha demethylase inhibitor | 1 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome | Isavuconazonium | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | Aug 21, 2026 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3390824, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets